Charles River Laboratories (CRL) is trading down at $301.59 (-1.11%) on NYSE/NASDAQ, as of the latest quote. It is a S&P 500 constituent in the Health Care sector.
Analyst price targets on CRL
Current price targets from 3 firms average $276, median $300, ranging from $219 to $310 — the average is 8% below the current $302. Each is tracked to its date and scored the same way a member's call is.
- JPMorgan $266 → $310 by Aug 2027 Aug 6, 2026 via Investing.com · JPMorgan's track record
- Evercore ISI $261 → $300 by Aug 2027 Aug 5, 2026 via Investing.com · Evercore ISI's track record
- CLSA $220 → $219 by Jul 2027 Jul 20, 2026 via Investing.com · CLSA's track record
Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.
Charles River Laboratories revenue & net income history (FY2016–FY2025)
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $1.68B | $1.86B | $2.27B | $2.62B | $2.92B | $3.54B | $3.98B | $4.13B | $4.05B | $4.02B |
| Growth (year over year) | +23.3% | +10.5% | +22.0% | +15.7% | +11.5% | +21.1% | +12.3% | +3.9% | −1.9% | −0.9% |
| Gross profit | $1.40B | $1.57B | — | — | — | — | — | — | — | — |
| Gross margin | 83.5% | 84.4% | — | — | — | — | — | — | — | — |
| Operating income | $237.6M | $288.3M | $331.4M | $351.2M | $432.7M | $589.9M | $651.0M | $617.3M | $227.3M | $25.2M |
| Operating margin | 14.1% | 15.5% | 14.6% | 13.4% | 14.8% | 16.7% | 16.4% | 14.9% | 5.6% | 0.6% |
| Net income | $154.8M | $123.4M | $226.4M | $252.0M | $364.3M | $391.0M | $486.2M | $474.6M | $22.2M | −$144.3M |
| Net margin | 9.2% | 6.6% | 10.0% | 9.6% | 12.5% | 11.0% | 12.2% | 11.5% | 0.5% | −3.6% |
| EPS (diluted) | $3.23 | $2.54 | $4.62 | $5.07 | $7.20 | $7.60 | $9.48 | $9.22 | $0.20 | −$2.91 |
| Balance sheet | ||||||||||
| Cash and equivalents | $117.6M | $163.8M | $195.4M | $238.0M | $228.4M | $241.2M | $233.9M | $276.8M | $194.6M | $213.8M |
| Total assets | $2.71B | $2.93B | $3.86B | $4.69B | $5.49B | $7.02B | $7.60B | $8.20B | $7.53B | $7.14B |
| Total liabilities | $1.86B | $1.87B | $2.52B | $3.03B | $3.35B | $4.43B | $4.58B | $4.54B | $4.02B | $3.92B |
| Long-term debt | $1.19B | $1.09B | $1.63B | $1.85B | $1.93B | $2.66B | $2.71B | $2.65B | $2.24B | $2.14B |
| Shareholders' equity | $836.8M | $1.05B | $1.32B | $1.63B | $2.11B | $2.53B | $2.98B | $3.60B | $3.46B | $3.16B |
| Cash flow | ||||||||||
| Operating cash flow | $316.9M | $318.1M | $441.1M | $480.9M | $546.6M | $760.8M | $619.6M | $683.9M | $734.6M | $737.6M |
| Capital expenditure | $55.3M | $82.4M | $140.1M | $140.5M | $166.6M | $228.8M | $324.7M | $318.5M | $233.0M | $219.2M |
| Free cash flow | $261.6M | $235.6M | $301.1M | $340.4M | $380.0M | $532.0M | $294.9M | $365.4M | $501.6M | $518.5M |
| Share buybacks | $12.3M | $106.9M | $13.8M | $18.1M | $24.0M | $40.7M | $38.7M | $24.2M | $119.2M | $360.7M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.01B | $1.00B | $984.2M | $1.03B | $1.00B | $994.2M | $995.8M | $1.00B |
| Growth (year over year) | −1.6% | −1.1% | −2.7% | +0.6% | −0.5% | −0.8% | +1.2% | −2.7% |
| Gross profit | $349.0M | — | — | — | — | — | — | — |
| Gross margin | 34.6% | — | — | — | — | — | — | — |
| Operating income | $117.4M | −$167.7M | $74.7M | $100.1M | $133.8M | −$283.4M | $119.9M | $119.9M |
| Operating margin | 11.6% | −16.7% | 7.6% | 9.7% | 13.3% | −28.5% | 12.0% | 11.9% |
| Net income | $69.7M | −$214.5M | $25.5M | $52.3M | $54.4M | −$276.6M | −$14.8M | −$1.48M |
| Net margin | 6.9% | −21.4% | 2.6% | 5.1% | 5.4% | −27.8% | −1.5% | −0.1% |
| EPS (diluted) | $1.33 | −$4.17 | $0.50 | $1.06 | $1.10 | −$5.57 | −$0.30 | −$0.03 |
| Balance sheet | ||||||||
| Cash and equivalents | $210.2M | $194.6M | $229.4M | $182.8M | $207.1M | $213.8M | $191.8M | $192.0M |
| Total assets | $8.00B | $7.53B | $7.58B | $7.56B | $7.51B | $7.14B | $7.73B | $7.53B |
| Total liabilities | $4.18B | $4.02B | $4.34B | $4.16B | $4.06B | $3.92B | $4.74B | $4.64B |
| Long-term debt | $2.33B | $2.24B | $2.51B | $2.33B | $2.19B | $2.14B | $2.66B | $2.62B |
| Shareholders' equity | $3.78B | $3.46B | $3.19B | $3.35B | $3.41B | $3.16B | $2.94B | $2.84B |
| Cash flow | ||||||||
| Operating cash flow | $251.8M | $159.4M | $171.7M | $204.6M | $213.8M | $147.5M | $41.1M | $179.7M |
| Capital expenditure | $38.7M | $75.6M | $59.3M | $35.3M | $35.6M | $89.0M | $55.9M | $31.1M |
| Free cash flow | $213.1M | $83.7M | $112.4M | $169.3M | $178.2M | $58.6M | −$14.8M | $148.6M |
| Share buybacks | $100.8M | $124.0K | $353.1M | $7.35M | $93.0K | $96.0K | $208.3M | $115.6M |
From Charles River Laboratories's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Charles River Laboratories
Charles River Laboratories International, Incorporated is an American life sciences company and contract research organisation (CRO) headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides products and services that support the development of drugs, vaccines, and other therapeutics. Its operations span at least 20 countries, offering research models, drug discovery and safety assessment, and manufacturing and testing services to pharmaceutical, biotechnology, government, and other clients.
Source: Wikipedia — Charles River Laboratories
- Headquarters
- Wilmington, Massachusetts From SEC filings, Oct 2026
Recent News (20)
-
Charles River Laboratories stock hits 52-week high at 303.33 USD
Charles River Laboratories stock hits 52-week high at 303.33 USD
-
Charles River Associates adds VP to life sciences unit
Charles River Associates adds VP to life sciences unit
-
NorthStrive Biosciences Partners with Charles River Laboratories to Advance Its EL-22 and EL-32 Engineered Probiotic Programs NorthStrive Biosciences Partners with Charles River Laboratories to Advance Its EL-22 and EL-32 Engineered Probiotic Programs
-
Jefferies raises Charles River Labs stock price target on cost efficiency outlook Jefferies raises Charles River Labs stock price target on cost efficiency outlook Investing.com
-
Jefferies raises Charles River Labs stock price target on cost efficiency outlook Jefferies raises Charles River Labs stock price target on cost efficiency outlook Investing.com UK
-
Charles River Laboratories International Inc Stock (CRL) Moved Up by 7.23% on Sep 24: Facts Behind the Movement Charles River Laboratories International Inc Stock (CRL) Moved Up by 7.23% on Sep 24: Facts Behind the Movement TradingKey
-
Charles River Associates at Sidoti conference: growth, AI and talent
Charles River Associates at Sidoti conference: growth, AI and talent
-
Charles River’s (CRL) Vaccine Push Meets A Bumpy Quarter
Charles River’s (CRL) Vaccine Push Meets A Bumpy Quarter
-
Charles River’s (CRL) New Automation Push Meets Old Margin Problems
Charles River’s (CRL) New Automation Push Meets Old Margin Problems
-
Here’s Why This Strategy Decided to Exit Charles River Laboratories (CRL)
Here’s Why This Strategy Decided to Exit Charles River Laboratories (CRL)
-
Charles River Laboratories at Morgan Stanley conference: growth inflection seen
Charles River Laboratories at Morgan Stanley conference: growth inflection seen
-
Is Wall Street Bullish or Bearish on Charles River Laboratories Stock?
Is Wall Street Bullish or Bearish on Charles River Laboratories Stock?
-
How an Insider CEO Is Taking a Fresh Look at Charles River
How an Insider CEO Is Taking a Fresh Look at Charles River
-
Charles River Laboratories (CRL) Q2 2026 Earnings Call Transcript
Charles River Laboratories (CRL) Q2 2026 Earnings Call Transcript
-
Charles River Associates Q2 Earnings Call Highlights Charles River Associates Q2 Earnings Call Highlights
-
Earnings call transcript: Charles River Associates tops Q2 2026 forecasts
Earnings call transcript: Charles River Associates tops Q2 2026 forecasts
-
Charles River Laboratories International Q2 Earnings Call Highlights Charles River Laboratories International Q2 Earnings Call Highlights
-
JPMorgan upgrades Charles River Labs stock rating on bookings
JPMorgan upgrades Charles River Labs stock rating on bookings
-
Charles River Laboratories International, Inc. Q2 2026 Earnings Call Summary Charles River Laboratories International, Inc. Q2 2026 Earnings Call Summary
-
Evercore ISI raises Charles River Labs stock price target on revenue growth
Evercore ISI raises Charles River Labs stock price target on revenue growth
More Health Care stocks
- CI Cigna
- CNC Centene Corporation
- COO Cooper Companies (The)
- COR Cencora
- CVS CVS Health
- DGX Quest Diagnostics
- DHR Danaher Corporation
- DVA DaVita